Every S-1 that Ispecimen Inc. (ISPC) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-1 covers the registration statement a company files to sell shares publicly, so if you follow ISPC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ISPC filings page.
iSpecimen Inc. is pursuing a primary, best‑efforts equity offering of up to 2,092,050 shares of common stock, Pre‑Funded Warrants to purchase up to 2,092,050 shares, and up to 2,092,050 underlying shares, for aggregate gross proceeds of up to $5,000,000. The assumed price is $2.39 per Share, matching the July 14, 2026 Nasdaq close.
Common stock outstanding was 1,522,359 shares as of July 14, 2026 and would increase to up to 3,614,409 shares if the full offering is sold and all Pre‑Funded Warrants are exercised. Each Pre‑Funded Warrant costs $2.3899, is exercisable at $0.0001 per share, and is subject to 4.99% (or 9.99% on notice) beneficial‑ownership caps.
Assuming all Shares are sold and no Pre‑Funded Warrants are issued, net proceeds are estimated at approximately $4,680,000, to be used for fees and expenses, repayment of outstanding debt, potential asset or business acquisitions, marketing and advertising (including up to $1,100,000 for IR Agency LLC), and general corporate and working capital needs. For 2025, revenue was $1,928,998 with a net loss of $10,487,532; for the quarter ended March 31, 2026, revenue was $156,009 and net loss $2,275,221. As of March 31, 2026, cash was $2,818,989, working capital was negative $2,115,634, and the company reported substantial doubt about its ability to continue as a going concern.
iSpecimen Inc. has filed an amended S-1 to register up to 1,515,152 shares of common stock, up to 1,515,152 pre-funded warrants, and 1,515,152 shares issuable upon warrant exercise in a best-efforts offering capped at $4,000,000.00.
The assumed price is $2.64 per share, matching the July 2, 2026 Nasdaq close for ISPC, with each pre-funded warrant priced at $2.6399 and carrying a $0.0001 exercise price. If all shares are sold, net proceeds are estimated at about $3.72M, earmarked for fees and expenses, non‑interest‑bearing outstanding liabilities, up to $700,000 for potential acquisitions, up to $1,000,000 for marketing with IR Agency LLC, and general working capital.
The company reverse‑split its stock 1‑for‑40 in April 2026 and had 1,522,359 shares outstanding as of July 2, 2026, rising to a maximum of 3,440,599 shares if the offering and warrant exercises are fully completed. iSpecimen’s 2025 revenue was $1,928,998 with a net loss of $10,487,532; Q1 2026 revenue was $156,009 with a net loss of $2,275,221. As of March 31, 2026, cash was $2,818,989 and working capital was negative $2,115,634, and auditors highlighted substantial doubt about the company’s ability to continue as a going concern.
iSpecimen Inc. is registering up to 1,544,402 shares of common stock and related pre-funded warrants in a best-efforts offering. At an assumed price of $2.59 per share, the potential raise is up to $4.0 million, with common shares outstanding rising from 1,437,157 to as many as 2,981,559.
The company plans to use net proceeds for placement agent fees, debt repayment, potential acquisitions, up to $1.0 million of marketing and advertising (including services from IR Agency LLC), and general working capital. iSpecimen operates an online biospecimen marketplace but remains loss-making, with a going concern warning, an accumulated deficit of $84.6 million, limited cash of $2.8 million, and a working capital deficit.
iSpecimen, Inc. filed an amended S-1 registration that describes a transactional biospecimen marketplace with concentrated revenue, recent capital raises, material liabilities, and operational and legal risks. The company reports its common shares outstanding prior to and after the offering are based on 8,211,156 shares as of October 6, 2025, and discloses significant customer concentration (one customer accounted for approximately 29% of 2024 revenue). Revenue is transactional and non‑recurring, sourced when researchers place specimen orders. The filing discloses a $1.0M loan issued with an 18% interest rate, ongoing sales tax liabilities (hundreds of thousands of dollars), and litigation and platform‑service disputes that caused a temporary marketplace shutdown in early 2025.
The company received a Nasdaq deficiency notice for minimum stockholders’ equity requirements and has submitted a compliance plan. Capital raises in 2024 included an ATM program that generated gross proceeds of approximately $1.49M and a registered securities offering that generated aggregate gross proceeds near $4.999M. The filing emphasizes operational risks—supplier reliance, international expansion, regulatory compliance, and revenue variability—and discloses an accumulated deficit and limited cash resources, creating ongoing financing dependence.